Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Revenue: 2016-2024

Historic Revenue for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Dec 2024 value amounting to $560.2 million.

  • Ultragenyx Pharmaceutical's Revenue rose 14.65% to $159.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.6 million, marking a year-over-year increase of 20.63%. This contributed to the annual value of $560.2 million for FY2024, which is 29.01% up from last year.
  • Ultragenyx Pharmaceutical's Revenue amounted to $560.2 million in FY2024, which was up 29.01% from $434.2 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Revenue high stood at $560.2 million for FY2024, and its period low was $271.0 million during FY2020.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Revenue value was $434.2 million (recorded in 2023), while the average stood at $452.6 million.
  • Data for Ultragenyx Pharmaceutical's Revenue shows a peak YoY spiked of 161.32% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Revenue stood at $271.0 million in 2020, then grew by 29.66% to $351.4 million in 2021, then grew by 3.39% to $363.3 million in 2022, then grew by 19.52% to $434.2 million in 2023, then rose by 29.01% to $560.2 million in 2024.